Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis

Rheumatology

Volumn 49, Issue 3, 2009, Pages 588-591

  Driessen, Rieke J B ^a   de Jong, Elke M G J ^a   Salemink, Gerrit W ^b   Bürer, Jan H G ^c   van de Kerkhof, Peter C M ^a   van den Hoogen, Frank H J ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zorgverzekeraars Nederland   (Netherlands)

^c SLINGELAND HOSPITAL   (Netherlands)

^d Sint Maartenskliniek ^*  (Netherlands)

Author keywords

Adalimumab; Biologic; Criteria; Etanercept; Infliximab; Joint; Methotrexate; Psoriatic arthritis; Reimbursement

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; HEALTH INSURANCE; HUMAN; NETHERLANDS; POLYARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REIMBURSEMENT; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; CHILD; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; NETHERLANDS; RECEPTORS, TUMOR NECROSIS FACTOR; REIMBURSEMENT MECHANISMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950542981     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep428     Document Type: Article

References (10)

1. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64.
2. Olivieri I, de Portu S, Salvarani C et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70.
3. Driessen RJ, de Jong EM, de Rie MA, Salemink GW, van de Kerkhof PC. Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis. Br J Dermatol 2008;159:760-1.
4. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl. 2):ii14-7.
5. Prevoo ML, Van't Hof MA, Kuper HH, van Leeuwen MA, van De Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
6. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778-83.
7. Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004;31:1293-6.
8. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
9. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
10. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009;11:R52.